CD274 and non-small cell lung carcinoma: A recent pooled analysis of 11 clinical trials has indicated that PD-L1 expression has an appreciable impact on clinical outcomes for patients with NSCLC treated with immunotherapy in the first- or second-line treatment setting (29).